Dyadic International appoints Michael Tarnok as the Chairman of its Board of Directors

– USA, FL – Dyadic International, Inc. (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok as the company’s Chairman of the Board of Directors. Mr. Tarnok will continue to serve on the company’s audit and compensation committees.

“As a former senior executive in manufacturing and finance at Pfizer, and experience as the Chairman of Keryx Biopharmaceuticals, Inc., Mike is the ideal candidate with relevant pharmaceutical and industry knowledge. Mike has already shown to be an asset to the Company since joining the board last year, and we expect that his insight and leadership will continue to be of great value to Dyadic, our employees and our shareholders. I am excited about Mike’s expanded role as it will allow me to better focus on how to best commercialize our C1 technology platform, grow enzyme revenues and accelerate the Company’s timeline to profitability. Additionally, in order to further strengthen and enhance our board of directors we are in the process of recruiting an additional independent director,” said Mark Emalfarb, Dyadic’s President and Chief Executive Officer.

“I am honored to be named Chairman of Dyadic’s Board and am extremely enthusiastic about the company’s future. In my expanded role, I will support Mark in continuing to provide the leadership and stewardship of the company that he has demonstrated over the past three decades. Dyadic has one of the strongest technology platforms in the industry as evidenced by our world-class partners including BASF, Abengoa, Sanofi Pasteur and others. This is a very exciting time for us. We are developing new and innovative products, building and expanding relationships with new and existing partners, and continuing to assemble a world-class management team,” said Mr. Tarnok.

Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is also the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx as a Director in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing. From 2000-2007, he served as Senior Vice President in Pfizer’s U.S. Pharmaceuticals Division. Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America. Mr. Tarnok earned an MBA in marketing from New York University and a Bachelor of Science in accounting from St. John’s University. He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.